oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma
Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Urology.ORCID-id: 0000-0001-5533-7899
Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Urology.ORCID-id: 0000-0003-0162-5881
Department of Urology, Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
School of Medical Sciences, Örebro University, Örebro, Sweden. (Clinical Epidemiology and Biostatistics)
Vise andre og tillknytning
2020 (engelsk)Inngår i: Applied immunohistochemistry & molecular morphology (Print), ISSN 1541-2016, E-ISSN 1533-4058, Vol. 28, nr 3, s. 213-220Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Programmed death ligand 1 (PD-L1) is a protein which, when interacting with its receptor programmed death 1, acts as a negative regulator of the antitumor T-cell-mediated immune response. The prognostic value of PD-L1 expression in renal cell carcinoma (RCC) has been controversial. In this study, the prognostic value of PD-L1 expression in RCC was evaluated by analyzing PD-L1 immunoreactivity in tumor cells and tumor-infiltrating immune cells (TIICs) in 346 RCC patients with long-term follow-up. PD-L1 positivity in tumor cells was associated with higher World Health Organization nucleolar grade (P<0.001), recurrence (P=0.011), and death due to RCC (P=0.031). PD-L1 positivity in TIICs was associated with higher nucleolar grade (P<0.001), higher T-stage (P=0.031), higher N-stage (P=0.01), recurrence (P=0.007), and death due to RCC (P=0.001). A significant positive association of time to cancer-specific death with both PD-L1-positive tumor cells and TIICs were also found. The data indicate that RCC patients with PD-L1-positive tumor cells and TIICs are at significant risk for cancer progression and the expression may be used as a complementary prognostic factor in the management of RCC patients.

sted, utgiver, år, opplag, sider
Lippincott Williams & Wilkins, 2020. Vol. 28, nr 3, s. 213-220
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-74192DOI: 10.1097/PAI.0000000000000766PubMedID: 31058656OAI: oai:DiVA.org:oru-74192DiVA, id: diva2:1315265
Tilgjengelig fra: 2019-05-13 Laget: 2019-05-13 Sist oppdatert: 2020-03-17bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Carlsson, JessicaSundqvist, Pernilla

Søk i DiVA

Av forfatter/redaktør
Carlsson, JessicaSundqvist, Pernilla
Av organisasjonen
I samme tidsskrift
Applied immunohistochemistry & molecular morphology (Print)

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 115 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf